Лечение артериальной гипертензии в XXI веке. Вопрос выбора монотерапии заменен на выбор рациональной комбинированной терапии

артериальная гипертензия, монотерапия, комбинирвоанная терапия, блокаторы ренин-ангиотензин-альдостероновой системы

1. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // Lancet. - 2002. - Vol. 360, № 9349. - P. 1903-1913.

2.

3. Mengen T., Uen S., Bramlage P. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility // Vasc. Health Risk Manag. - 2009. - Vol. 5. - P. 1043-1058. 3.

4.

5. Всероссийское научное общество кардиологов. Национальные клинические рекомендации. - М., 2009. - С. 7-34.

6.

7. Mancia G., De Backer G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22De%20Backer%20G%22%5BAuthor%5D>., Dominiczak A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dominiczak%20A%22%5BAuthor%5D>. et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. - 2007. - Vol. 28, № 12. - P. 1462-1536.

8.

9. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. - 2009. - Vol. 27, № 11. - P. 212-215.

10.

11. Wolf-Maier K., Cooper R.S., Kramer H. et al. Hypertension treatment and control in five European countries, Canada, and the United States // Hypertension. - 2004. - Vol. 43, № 1. - P. 10-17.

12.

13. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data // Lancet. - 2005. - Vol. 365, № 9455. - P. 217-223.

14.

15. Gaddam K.K., Oparil S. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? // Curr. Opin. Nephrol. Hypertens. - 2008. - Vol. 17, № 5. - P. 484-490.

16.

17. Pimento E., Oparil S. Role of aliskeren in cario-renal protection and use in hypertensives with multiple risk factors // Vasc. Health Risk Manag. - 2009. - Vol. 5. - P. 453-463. 10.

18.

19. PROGESS Collaborative Study Group. Randomised trial period of perindopril-based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischemic attack // Lancet. - 2001. - Vol. 358, № 9287. - P. 1033-1041.

20.

21. Marre M., Puig J.G., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study // J. Hypertens. - 2004. - Vol. 22, № 8. - P. 1613-1622. 12.

22.

23. Dahlöf B., Gosse P., Guéret P. et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study // J. Hypertens. - 2005. - Vol. 23, № 11. - P. 2063-2070. 13.

24.

25. ADVANCE Collaborative Group. Rationale and design of the ADVANCE Study: a randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 diabetes mellitus // J. Hypertens. - 2001. - Vol. 19, Suppl. 4. - P. S21-S28. 14.

26.

27. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. - 2007. - Vol. 370, № 9564. - P. 829-840.

28.

29. Campbell N.R.C., Leiter L.A., Lachochelle P. et al. Hypertension in diabetes: a call to action // Can. J. Cardiol. - 2009. - Vol. 25, № 5. - P. 299-302.

30.

31. Leenen F.H., Dumais J., McInnis N.H. et al. Results of the Ontario survey on the prevalence and control of hypertension// Can. Med. Assoc. J. - 2008. - Vol. 178, № 11. - P. 1441-1449.

32.

33. Tuomilehto J., Rastenyte D., Birkenhager W.H. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators // N. Engl. J. Med. - 1999. - Vol. 340, № 9. - P. 677-684. 18.

34.

35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 // Br. Med. J. - 1998. - Vol. 317, № 7160. - P. 703-713.

36.

37. Hansson L., Zanchetti A., Carson D.S. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial // Lancet. - 1998. - Vol. 351, № 9142. - P. 1755-1761.

38.

39. Mourad J., Waeber B., Zannad F. et al. on behalf of the investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach // J. Hypertens. - 2004. - Vol. 22, № 12. - P. 2386.

40.

41. Mogensen C.E., Viberti G., Halimi S. et al. Effect of a low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER // Hypertens. - 2003. - Vol. 41, № 5. - P. 1063-1071.

42.

43. Asmar R.G., London G.M., O'Rourke M.F. Safar M.E. on behalf of the REASON Project Coordinators and investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol <http://www.ncbi.nlm.nih.gov/pubmed/11641310> // Hypertension. - 2001. - Vol. 38. - P. 922-926.

44.

45. Mourad J.J., Hanon O., Deverre J.R. et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study // J. Renin Angiotensin Aldosterone Syst. - 2003. - Vol. 4, № 2. - P. 94-95.